top of page
Executive Spotlights

Bristol Myers Squibb Continues Expansion with $4.1B Acquisition of RayzeBio

New Jersey, December 26, 2023 (Reuters) -- Bristol Myers Squibb (BMY.N) announced its intention to acquire RayzeBio (RYZB.O) for approximately $4.1 billion, aimed at strengthening its cancer drug business. This move represents the drugmaker's second multi-billion-dollar deal within a week. Prior to this, on Friday, Bristol Myers had disclosed a $14 billion acquisition of Karuna Therapeutics (KRTX.O), a company specializing in schizophrenia drugs. Notably, these developments come in the wake of the appointment of Chris Boerner as the new CEO of Bristol Myers, a role he officially assumed nearly two months ago.

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page